Lantus, the new long-acting insulin
May 2002
Patients are asking about Lantus, the new long-acting insulin.
Health Canada has approved Lantus (insulin glargine)...but Aventis is delaying the launch until they have adequate supplies.
Insulin glargine is a synthetic insulin that differs from human insulin by 3 amino acids. It forms a microprecipitate in subcutaneous tissue...which delays and prolongs its absorption.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive